Conference Correspondent  - Conference Correspondent, ASH
Ali McBride, PharmD, MS, BCPS
Clinical Coordinator
The University of Arizona Cancer Center
Tucson, AZ

Ali McBride provides an overview of the role of the pharmacist and the importance of working with a broad team of healthcare providers in managing patients on oral oncolytics.

That's an excellent question. Right now, I work with a team of advanced practitioners, physicians, healthcare providers, and also finance to actually obtain a drug therapy for patients looking at dose adjustments, and also looking at compliance, or adherence for certain type of therapies.

We actually have a multi‑factorial role with multi‑disciplinary based evaluations for patients on oral oncolytics at this point. We have multiple roles, would be a better word for this. Making sure the patient is actually getting the drug which oftentimes for any first dose drug in the oral oncolytic, some patients may not even pick up that prescription, or even work on that prescription for several weeks later.

They're not even starting that therapy until a later time point. We have difficulties there as well. In addition, we also make sure the patient is getting the drug therapy. Sometimes, finance is a barrier.

Out of pocket expense has become an issue. We have seen a lot of work in regards to oral chemotherapy parity in which we're making sure the patients can actually afford those copays. Based on estate base legislation issues at each state across the country is also a federal act that's still in the pipeline right now.

We have numerous types of focuses. It may depend on the patient, it may depend on the physician, and what they want as well, but the goal is to make sure the patient has access to therapies, and they're adherent to therapies to make sure they maximize their outcomes with their treatment.

Related Items
Polatuzumab Vedotin plus R-CHP Outperforms Standard of Care in Treatment of DLBCL
TOP - March 2022 Vol 15, No 2 published on March 16, 2022 in ASH
Time-Limited Venetoclax-Based Regimens Demonstrate Promising Efficacy in Fit Patients with CLL
TOP - March 2022 Vol 15, No 2 published on March 16, 2022 in ASH
Mosunetuzumab Induces Deep Remissions in Patients with Relapsed/Refractory Follicular Lymphoma
William King
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in ASH
Results from 2 Studies Provide Insights on Antibody Response to COVID-19 Vaccines in Patients with Hematologic Malignancies
William King
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in ASH
CAR T-Cell Therapies Show Efficacy in Second-Line Treatment of Large B-Cell Lymphoma
William King
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in ASH
An Expert Perspective on the Current and Future of Maintenance Therapy in Ovarian Cancer
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, Ali McBride, PharmD, MS, BCPS
Videos published on November 30, 2020 in Interview with the Innovators, Video, Ovarian Cancer
Immunotherapy in Combination with PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, Ali McBride, PharmD, MS, BCPS
Videos published on November 13, 2020 in Interview with the Innovators, Video
Adverse Events and Improvements in Quality of Life Associated with First-Line Maintenance Therapy in Ovarian Cancer
Paula Anastasia, RN, MN, AOCN, Ali McBride, PharmD, MS, BCPS
Videos published on November 2, 2020 in Interview with the Innovators, Video
Management of Adverse Events Associated with PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
Ali McBride, PharmD, MS, BCPS, Paula Anastasia, RN, MN, AOCN
Videos published on October 11, 2020 in Interview with the Innovators, Video
Combination Therapy as Maintenance in Ovarian Cancer
Amina Ahmed, MD, Ali McBride, PharmD, MS, BCPS, Paula Anastasia, RN, MN, AOCN
Videos published on October 6, 2020 in Interview with the Innovators, Video
Last modified: July 22, 2021